Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (Vagivital^® Gel) in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy: A Randomized, Double-Blind Controlled Study.

Primary Efficacy Endpoint Most Bothersome VVA Symptom Highly significant (p<0.0001, See Table 1 ) improvements from baseline at both 4 weeks and 12 weeks follow-up for the most bothersome VVA symptom, of which dyspareunia and vaginal dryness were the most frequently occurring, were noted in both groups.

also in 132,142 other papers